Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

Peter J. Houghton; Raushan T. Kurmasheva; E. Anders Kolb; Jianrong Wu; Richard Gorlick; John M. Maris; Malcolm A. Smith

doi:10.1002/pbc.24756

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

Peter J. Houghton, Raushan T. Kurmasheva, E. Anders Kolb, Jianrong Wu, Richard Gorlick, John M. Maris, Malcolm A. Smith

Internal Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

TAK-701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c-Met transduced signaling and c-Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK-701 based on immunochemical detection of HGF/c-Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK-701 was tested using a dose of 30mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK-701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts.

Original language	English
Pages (from-to)	380-382
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	61
Issue number	2
DOIs	https://doi.org/10.1002/pbc.24756
State	Published - Feb 2014

Keywords

C-Met inhibition
Developmental therapeutics
Preclinical testing

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.24756

Cite this

@article{185d30c67202413ab7f5094c61634601,

title = "Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program",

abstract = "TAK-701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c-Met transduced signaling and c-Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK-701 based on immunochemical detection of HGF/c-Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK-701 was tested using a dose of 30mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK-701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts.",

keywords = "C-Met inhibition, Developmental therapeutics, Preclinical testing",

author = "Houghton, {Peter J.} and Kurmasheva, {Raushan T.} and Kolb, {E. Anders} and Jianrong Wu and Richard Gorlick and Maris, {John M.} and Smith, {Malcolm A.}",

year = "2014",

month = feb,

doi = "10.1002/pbc.24756",

language = "English",

volume = "61",

pages = "380--382",

number = "2",

}

TY - JOUR

T1 - Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

AU - Houghton, Peter J.

AU - Kurmasheva, Raushan T.

AU - Kolb, E. Anders

AU - Wu, Jianrong

AU - Gorlick, Richard

AU - Maris, John M.

AU - Smith, Malcolm A.

PY - 2014/2

Y1 - 2014/2

N2 - TAK-701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c-Met transduced signaling and c-Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK-701 based on immunochemical detection of HGF/c-Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK-701 was tested using a dose of 30mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK-701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts.

AB - TAK-701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c-Met transduced signaling and c-Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK-701 based on immunochemical detection of HGF/c-Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK-701 was tested using a dose of 30mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK-701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts.

KW - C-Met inhibition

KW - Developmental therapeutics

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=84890862865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890862865&partnerID=8YFLogxK

U2 - 10.1002/pbc.24756

DO - 10.1002/pbc.24756

M3 - Article

AN - SCOPUS:84890862865

SN - 1545-5009

VL - 61

SP - 380

EP - 382

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 2

ER -

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this